Bevacizumab followed by atezolizumab versus both together for advanced hepatocellular carcinoma with MASLD

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized phase 2/3 study will enroll 20 patients with advanced, unresectable hepatocellular carcinoma and moderate-to-severe MASLD and assign them to either sequential or concurrent bevacizumab plus atezolizumab for up to six months with follow-up. Primary clinical endpoints include objective response rate, progression-free survival, disease control rate, and overall survival, with safety monitored by CTCAE v5.0. Serial liver biopsies and biomarker testing will analyze tumor microenvironment changes (including T-cell calcium signaling, VEGFA expression, and other immune factors) before and after treatment. The study will also explore how baseline metabolic measures (blood lipids, insulin resistance) relate to treatment response.

Why it matters

Who can join: the full rules

Eligibility Criteria Inclusion Criteria

* Age ≥ 18 years old (gender not limited)
* ECOG performance status of 0-1
* Preoperative imaging diagnosis of advanced hepatocellular carcinoma (BCLC stage C or D, unsuitable for surgery)
* Ultrasound or MRI indicating moderate to severe fatty liver (Fibroscan CAP \> 268 dB/m or MR fat score \> 10%)
* Willing to use contraceptive measures during the trial period
* Expected survival time ≥ 3 months
* At least one measurable lesion (per RECIST 1.1) that has not been irradiated
* Organ function levels (within 7 days before first study medication) must meet the following:
* Hematopoietic function: ANC ≥ 1.5×10⁹/L, PLT ≥ 100×10⁹/L, Hb ≥ 90 g/L, no transfusion within 14 days
* Liver function: TBIL ≤ 1.5×ULN, AST/ALT/ALP ≤ 2.5×ULN, serum creatinine ≤ 1.5×ULN, CrCl ≥ 50 mL/min, ALB ≥ 30 g/L, Child-Pugh A
* Coagulation function: INR and APTT ≤ 1.5×ULN or within therapeutic range if on anticoagulants
* Renal function: urinary protein ≤ 1+ (or ≤1 g/24h if \>1+)
* Cardiac function: ECG normal or clinically insignificant, LVEF \> 50%
* Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dosing
* Men and women of reproductive potential must use effective contraception during and for 12 months after treatment
* Participants must voluntarily provide informed consent and have good compliance

Exclusion Criteria

* Excessive alcohol consumption (weekly ethanol intake: males \< 210 g, females \< 140 g)
* Tumor lesions previously treated with targeted therapy, immunotherapy, TACE, or radiotherapy
* Pregnant or breastfeeding women, or positive pregnancy test at baseline
* Central nervous system metastases diagnosed by CT, MRI, or PET-CT
* Participation in another clinical drug or therapy trial within 4 weeks before first study dose
* Major surgery within 4 weeks prior to first study dose, or incomplete recovery from surgery
* Radiotherapy within 2 weeks before first study dose
* History or presence of primary immunodeficiency or active autoimmune disease
* History of organ transplantation or hematopoietic stem cell transplantation
* Current use of immunosuppressants or corticosteroids (\>10 mg/day prednisone or equivalent) within 2 weeks
* Positive for HIV antibody or Treponema pallidum antibody, or active hepatitis B/C infection
* Allergy to recombinant humanized PD-1 monoclonal antibody, VEGF monoclonal antibody, or components
* Symptomatic pleural effusion, pericardial effusion, or ascites requiring clinical intervention
* Severe cardiovascular disease within 12 months (e.g., CAD, CHF ≥ II, arrhythmias, MI)
* Events within 6 months before first dose (e.g., DVT, PE, MI, PCI, ACS, CABG, stroke, TIA, embolism)
* History of GI surgery, obstruction, bleeding, dysfunction, or malabsorption affecting drug absorption
* Severe uncontrolled infection or comorbidity, or moderate/severe renal impairment
* Active pulmonary disease (interstitial pneumonia, COPD, asthma, tuberculosis history)
* Abnormal coagulation (INR \> 2.0, PT \> 16 s), bleeding tendency, or thrombolytic/anticoagulant therapy (except prophylaxis)
* Significant bleeding within 3 months (e.g., hemoptysis ≥ 2.5 mL, GI bleeding, varices, ulcers, vasculitis)
* Known hereditary/acquired bleeding or thrombotic disorders (e.g., hemophilia, thrombocytopenia)
* History of substance abuse or mental disorders affecting compliance
* Use of warfarin or coumarin derivatives within 14 days before or during treatment
* Other severe acute/chronic conditions increasing risk or confounding results
* Poor compliance or other conditions deemed unsuitable for trial participation

Where it's running

• Eastern Hepatobiliary Surgery Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Hao Shen, M.D.
• Email: shenhaochina@163.com
• Phone: 18952681068

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI system to predict response to Atezolizumab-Bevacizumab in unresectable liver cancer

  This study looks at whether an artificial intelligence tool can predict how patients with unresectable hepatocellular carcinoma will respond to atezolizumab-bevacizumab.

  Recruiting First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT07495735

• Fecal microbiota transfer to overcome resistance to atezolizumab/bevacizumab in liver cancer

  This will test whether adding fecal microbiota transfer to standard atezolizumab/bevacizumab helps adults with advanced hepatocellular carcinoma respond better.

  Recruiting Phase 2 University Hospital Heidelberg · Heidelberg, Baden-Wurttemberg and 6 other locations · NCT05690048

• Blood biomarkers to predict response to atezolizumab plus bevacizumab in hepatocellular carcinoma

  This study tests whether blood-based biomarkers can predict which patients with advanced liver cancer will respond to first-line atezolizumab plus bevacizumab.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07734857

• Combining two immunotherapies, a bevacizumab biosimilar, and liver-artery chemotherapy to shrink advanced liver cancer for possible surgery

  This treatment will try a combo of two immune drugs (sintilimab and ipilimumab N01), a bevacizumab biosimilar, and hepatic arterial infusion chemotherapy to shrink unresectable intermediate-to-advanced hepatocellular carcinoma so more patients can become eligible for surgery.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07560488

• TIPS benefits for people with hepatocellular carcinoma taking Tecentriq (atezolizumab) plus Avastin (bevacizumab) as first-line therapy.

  This study will try to see if placing a TIPS device helps people with advanced or unresectable hepatocellular carcinoma who are starting first-line treatment with Tecentriq plus Avastin.

  Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Düsseldorf, North Rhine-Westphalia · NCT07365930

• Using fecal microbiota transplantation to try to restore response to atezolizumab and bevacizumab in people with unresectable hepatocellular carcinoma.

  This will try whether giving a fecal microbiota transplant and then restarting atezolizumab plus bevacizumab can restore treatment response in adults with unresectable HCC who progressed early on those drugs.

  Recruiting Phase 2 IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, BO · NCT07276100

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.